Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03205332
Other study ID # 2015-146-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 12, 2015
Est. completion date October 28, 2019

Study information

Verified date December 2019
Source Ryerson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Generalized Anxiety Disorder (GAD) is a chronic condition whose hallmark feature is excessive and uncontrollable worry (American Psychiatric Association, 2013). Theories of GAD propose that specific cognitive biases are involved in the maintenance and etiology of chronic worry. One cognitive bias that plays a role in worrying is abstract thinking, or the tendency to "verbalize" thoughts and worries in a manner that is vague and lacking in detail. There is evidence that training depressed people to think more concretely improves depressive symptoms and depression-type thinking styles, and reduces emotional reactivity. Given that chronic worry and depression have commonalities (e.g., repetitive thinking styles, difficulties with problem-solving and attentional control, emotion dysregulation), concreteness training may help people who struggle with chronic worry. The main goals of this proof of concept experiment are 1) to test in individuals reporting chronic worry the effects of an active form of concreteness training that involves imagery practice (compared to a no training control condition) on frequency of worrying, problem solving quality, and worry-related processes; 2) to examine the degree to which concreteness training causes improvements in daily worry and negative affect during the 7 days of practice. The study design will provide us with an understanding on a more "macro" level of the potential short-term benefits and will at the same time allow us to see, on a more "micro" level, how training concreteness affects worry and mood on a day-to-day basis during a 7-day period. The findings from this study will inform relevant clinical literature about efficacious methods to reduce chronic worry.


Description:

The main goals of this proof of concept experiment are 1) to test in individuals reporting chronic worry the effects of an active form of concreteness training that involves imagery practice (compared to a no training control condition) on frequency of worrying, problem solving quality, and worry-related processes; 2) to examine the degree to which concreteness training causes improvements in daily worry and negative affect during the 7 days of practice. Participants are recruited from the community via advertisements. Following a telephone screen, participants attend a baseline visit during which they complete the MINI interview. Those who continue to be eligible complete the outcome measures and are randomly assigned to either the experimental condition or the control condition. Participants assigned to the experimental condition receive training in concrete processing and learn how to complete the daily experience sampling diary. Participants assigned to the control condition do not receive training and learn how to complete the daily experience sampling diary. All participants then complete their assigned activities for 7 days. They then return to the lab to complete the outcome measures at post-test, 1 week follow up and 1 month follow up. Participants are then debriefed.


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date October 28, 2019
Est. primary completion date October 28, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion:

1. Penn State Worry Questionnaire (trait) score meeting threshold of 65 or higher.

2. Endorsement of symptoms consistent with Generalized Anxiety Disorder on the MINI interview with a CSR equal to or greater than 4.

3. If other symptoms are present, associated CSR is at least 1 point lower than the CSR associated with GAD symptoms

Exclusion

1. Having a current or past history of mania or psychosis, or endorsement of symptoms consistent with a substance use disorder in the past 12 months.

2. Reporting of suicidal ideation, intent or plan.

3. Participants are excluded if they are currently receiving psychological treatment or counseling unless this treatment is infrequent (meeting once monthly or less) or the participant has been receiving consistent weekly treatment for 12 weeks and still meets all other eligibility criteria.

4. Psychotropic medication with a change in dose in the past 12 weeks. If they have recently discontinued a psychotropic medication, they will be included if it has been at least 1 month since discontinuation or 3 months in the case of fluoxetine.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Concreteness Training


Locations

Country Name City State
Canada Psychology Research and Training Centre, Ryerson University Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Ryerson University Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

References & Publications (3)

Borkovec TD, Inz J. The nature of worry in generalized anxiety disorder: a predominance of thought activity. Behav Res Ther. 1990;28(2):153-8. — View Citation

Stöber, J. & Borkovec, T.D. (2002). Reduced concreteness of worry in generalized anxiety disorder: Findings from a therapy study. Cognitive Therapy and Research, 26, 89 - 95.

Watkins ER, Baeyens CB, Read R. Concreteness training reduces dysphoria: proof-of-principle for repeated cognitive bias modification in depression. J Abnorm Psychol. 2009 Feb;118(1):55-64. doi: 10.1037/a0013642. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change in trait anxiety as measured by STICSA Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1 month follow up
Other Change in mood/affect as measured by PANAS Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up.
Other Change in intolerance of uncertainty as measured by the Intolerance of Uncertainty Scale Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up
Other Change in emotion dysregulation as measured by the DERS Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up
Other Change in distress tolerance as measured by the Distress Tolerance Scale Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up
Other Change in imagery use as measured by the Spontaneous Use of Imagery Scale [ Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up
Primary Change in worry as measured by the Penn State Worry Questionnaire - Past Week this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in depressive symptoms as measured by the Centre for Epidemiological Studies Depression Scale this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in negative problem orientation as measured by the Negative Problem Orientation Questionnaire this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in quality of problem-solving as measured by The Means-Ends Problem-Solving task this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in problem solving style as measured by the Social Problem Solving Inventory Revised Administered at baseline, at post-test (1 week post baseline), at 1-week follow up and at 1-month follow up
Secondary Change in attentional control as measured by the Attentional Control Scale this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in residual working memory capacity as measured by the Random Interval Generation Task this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary - Change in interpretation bias as measured by the Ambiguous/ Unambiguous Situations Diary Extended this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in cognitive avoidance as measured by the Cognitive Avoidance Questionnaire this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
Secondary Change in worry as measured by experience sampling completed during the 7 days between baseline and post test Daily during 7-day intervention period
Secondary Change in affect as measured by experience sampling completed during the 7 days between baseline and post test Daily during 7-day intervention period
Secondary Change in concreteness as measured by experience sampling completed during the 7 days between baseline and post test. Daily during 7-day intervention period
Secondary Change in GAD-Q-IV severity this measure is administered at baseline, at post-test (1 week post baseline), at 1 week follow up and at 1 month follow up
See also
  Status Clinical Trial Phase
Completed NCT00390533 - An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder Phase 3
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT04702711 - Experiences of Anger in Patients in Primary Health Care With Symptoms of Generalized Anxiety
Active, not recruiting NCT04751864 - Brain Stimulation & Generalized Anxiety Study Phase 4
Completed NCT02678624 - Project Collabri for Treatment of Anxiety N/A
Active, not recruiting NCT04386291 - Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19 N/A
Completed NCT04356365 - The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)
Not yet recruiting NCT04442360 - The Impact of Information Sources on Mental Health During the COVID-19 Pandemic
Not yet recruiting NCT04183946 - Willkommen Mutterglück: Online CBT for Pregnant and Postpartum Women With Depression and Anxiety N/A
Not yet recruiting NCT03445143 - GATE: Generalized Anxiety - A Treatment Evaluation N/A
Not yet recruiting NCT04378257 - Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic Phase 3
Recruiting NCT03528109 - Improving Access to Child Anxiety Treatment N/A
Not yet recruiting NCT03015285 - CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT N/A
Completed NCT04510519 - Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
Completed NCT00417118 - An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder Phase 3
Recruiting NCT06146530 - Cerina-A Pilot Randomized Controlled Trial N/A
Completed NCT02872051 - Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Anxiety and Depression N/A
Completed NCT02148042 - Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa
Recruiting NCT05292807 - Imagery Rescripting and Imaginal Exposure for Anxiety Symptoms N/A